Renal Denervation for the Treatment of Hypertension: Making a New Start, Getting It Right

Journal of Clinical Hypertension

Volumn 17, Issue 10, 2015, Pages 743-750

  Weber, Michael A ^a   Kirtane, Ajay ^b   Mauri, Laura ^c   Townsend, Raymond R ^d   Kandzari, David E ^e   Leon, Martin B ^b  

^a SUNY DOWNSTATE MEDICAL CENTER   (United States)

^b Department of Medicine   (United States)

^c HARVARD CLINICAL RESEARCH INSTITUTE   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e PIEDMONT HEART INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROCHLOROTHIAZIDE; SPIRONOLACTONE; THIAZIDE DIURETIC AGENT;

ALGORITHM; CLINICAL PROTOCOL; DRUG DOSE INCREASE; DRUG TARGETING; EDITORIAL; HUMAN; HYPERTENSION; KIDNEY DENERVATION; KIDNEY NERVE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RENIN RELEASE; SODIUM RETENTION; SYMPATHETIC TONE; CATHETER ABLATION; INNERVATION; KIDNEY; PROCEDURES; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYMPATHECTOMY; TREATMENT FAILURE;

CATHETER ABLATION; HUMANS; HYPERTENSION; KIDNEY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SYMPATHECTOMY; TREATMENT FAILURE;

EID: 84942820557     PISSN: 15246175     EISSN: 17517176     Source Type: Journal    
DOI: 10.1111/jch.12590     Document Type: Editorial

References (15)

1. Smithwick RH, Thompson JE. Splanchnicectomy for essential hypertension: results in 1, 266 cases. JAMA. 1953;152:1501-1504.
2. DiBona GF, Kopp UC. Neural control of renal function. Physiol Rev. 1997;77:75-197.
3. Krum H, Schlaich M, Whitbourn R. Catheter-based renal sympathetic denervation for resistant hypertension: a multi-centre safety and proof-of-principle cohort study. Lancet. 2009;373:1275-1281.
4. Esler MD, Krum H, Sobotka PA, et al; SYMPLICITY HTN-2 Investigators. Renal sympathetic denervation in patients with treatment-resistant hypertension (the SYMPLICITY HTN-2 Trial): a randomized controlled trial. Lancet. 2010;376:1903-1909.
5. Bhatt DL, Kandzari DE, O'Neill WW, et al; SYMPLICITY HTN-3 Investigators. A controlled trial of renal denervation for resistant hypertension. N Engl J Med. 2014;370:1393-1401.
6. Kandzari DE, Bhatt DL, Brar S, et al. Predictors of blood pressure response in the SYMPLICITY HTN-3 trial. Eur Heart J. 2015;36:219-227.
7. Atherton DS, Deep NL, Mendelsohn FO. Microanatomy of the renal sympathetic nervous system: a human post-mortem histologic study. Clin Anat. 2012;25:628-633.
8. Schwerg M, Heutel C, Strajnic D. Renal sympathetic denervation: early impact on ambulatory resistant hypertension. J Clin Hypertens (Greenwich). 2014;16:406-411.
9. Ewen S, Ukena C, Linz D, et al. Reduced effect of percutaneous renal denervation on blood pressure in patients with isolated systolic hypertension. Hypertension. 2015;65:193-199.
10. The SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA. 1991;265:3255-3264.
11. Beckett NS, Peters R, Fletcher AE, et al; HYVET Study Group. Treatment of hypertension in patients 80 years of age or older. N Engl J Med. 2008;358:1887-1898.
12. White WB, Weber MA, Sica D, et al. Effects of the angiotensin receptor blocker azilsartan medoxomil versus olmesartan and valsartan on ambulatory and clinic blood pressure in patients with stages 1 and 2 hypertension. Hypertension. 2011;57:413-420.
13. Calhoun DA, Jones D, Textor S, et al. Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation. 2008;117:e510-e526.
14. Lacourciere Y, Crikelair N, Glazer RD, et al. 24-hour ambulatory blood pressure control with triple-therapy amlodipine, valsartan and hydrochlorothiazide in patients with moderate to severe hypertension. J Hum Hypertens. 2011;25:615-622.
15. Azizi M, Sapoval M, Gosse P, et al. Optimum and stepped care standardised antihypertensive treatment with or without renal denervation for resistant hypertension (DENERHTN): a multicentre, open-label, randomised controlled trial. Lancet. 2015Jan 23; DOI: http://dx.doi.org/10.1016/S0140-6736(14)61942-5.